IBJNews

Trade agency to probe Lilly's infringement claim

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co.’s patent- infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.

The U.S. International Trade Commission in Washington, D.C., said Thursday it will probe the complaint Lilly filed Jan. 20. Indianapolis-based Lilly claims Hospira’s gemcitabine, Gemzar’s active ingredient, infringes a patent that doesn't expire until February 2014.

Global sales of Gemzar, used to treat lung, breast, pancreatic and ovarian cancer, dropped 22 percent, to $243.6 million, in the fourth quarter, Lilly reported Jan. 27. Lake Forest, Ill.-based Hospira began selling gemcitabine in November after Lilly lost an appeals court ruling that said a separate patent expiring in May 2013 was invalid.

The patented method is “the most commercially viable process available for manufacturing gemcitabine” and “involves less steps, higher yields and lower costs,” Lilly said in its complaint.

Hospira sued Lilly in September, seeking a court ruling that its process wouldn’t infringe the patent. That case is pending in federal court in Chicago.

The Lilly ITC complaint also names Hospira suppliers Jiangsu Hansoh Pharmaceutical Co. of China, Intas Pharmaceuticals Ltd. of India and ChemWerth Inc. of Woodbridge, Conn. According to Lilly, Hansoh makes the active ingredient, ships it to India where it’s formulated into the drug before being sent to ChemWerth for sale by Hospira.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
ADVERTISEMENT